KYMR Form 4: CFO Executes 10b5-1 Plan, Sells 79,220 Shares at $50 Avg
Rhea-AI Filing Summary
Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, reported multiple transactions under a Rule 10b5-1 trading plan adopted September 6, 2024. On 09/17/2025 he acquired 79,220 shares of Kymera common stock at $2.08 (via exercise of options) and sold 79,220 shares at a weighted-average price of $50.0048 (sales executed across prices $49.90–$50.25). After the transactions the filing reports 306,629 shares beneficially owned before the sale and 227,409 shares following the sale. The report discloses two stock option transactions with exercise price $2.08 that were fully vested and exercisable, and notes 523 shares were earlier acquired under the employee stock purchase plan on June 2, 2025.
Positive
- Transactions executed under a Rule 10b5-1 plan, providing pre-established timing and compliance clarity
- Options were fully vested and exercisable prior to exercise, as disclosed
- Detailed sale pricing range and weighted-average price provided for transparency
- Form includes prior ESPP acquisition disclosure (523 shares)
Negative
- Large sale of 79,220 shares reduced beneficial ownership from 306,629 to 227,409 shares
Insights
TL;DR: Routine insider option exercises and offsetting sales under a 10b5-1 plan; transaction size is disclosed but appears procedural.
The filing documents a common pattern where an executive exercises fully vested options at a low exercise price ($2.08) and sells the resulting shares under a pre-established Rule 10b5-1 plan, realizing proceeds at a weighted-average sale price of $50.0048. The transactions changed beneficial ownership from 306,629 to 227,409 shares. These actions are transparent and accompanied by standard disclosures, including the 10b5-1 plan adoption date and a price range for the multiple sales. From a financial perspective, the exercise and sale crystallize value from long-standing equity compensation rather than signaling an unplanned disposition.
TL;DR: Disclosure follows accepted governance practice: use of a 10b5-1 plan and clear footnotes on vesting and sale pricing.
The Form 4 provides required details: reporting person role (CFO), relation to issuer, Rule 10b5-1 plan reference (dated 09/06/2024), and explicit footnotes on vesting and sale pricing across a stated range. It also includes signature and explanatory notes. These elements support compliance with Section 16 reporting norms and reduce ambiguity about timing and intent by tying sales to a pre-authorized trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 42,246 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 36,974 | $0.00 | -- |
| Exercise | Common Stock | 79,220 | $2.08 | $165K |
| Sale | Common Stock | 79,220 | $50.0048 | $3.96M |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option are fully vested and exercisable.
